/
IMNM
$26.42-$1.57 (-5.61%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.2B
114M shares
52-week range
$8.67 – $28.62
89% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$12.09
Immunome, Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
www.immunome.com- Employees
- 177
- IPO / List date
- Oct 2, 2020
- HQ
- BOTHELL, WA
Held by traders on TradeandTell
No one on the platform currently holds IMNM.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 68,902 | $1.5M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2007-12-19 | 1-for-1000reverse |
Recent trades on TradeandTell
No one on the platform has traded IMNM yet.
